David Horrobin (English Wikipedia)

Horrobin DF (1991). "Interactions between n-3 and n-6 essential fatty acids (EFAs) in the regulation of cardiovascular disorders and inflammation". Prostaglandins Leukot Essent Fatty Acids. 44 (2): 127–31. doi:10.1016/0952-3278(91)90196-C. PMID 1745654.
Stein J (2004). "David Horrobin (1939–2003): a memoir". Prostaglandins Leukot. Essent. Fatty Acids. 70 (4): 339–43. doi:10.1016/j.plefa.2004.01.001. PMID 15085824.
Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, Thompson JR, Chapman T, Berth-Jones J (13 December 2003). "Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial". BMJ. 327 (7428): 1385–0. doi:10.1136/bmj.327.7428.1385. PMC 292992. PMID 14670885.
Horrobin, David F. (2003). "Modern biomedical research: an internally self-consistent universe with little contact with medical reality?". Nature Reviews Drug Discovery. 2 (2): 151–154. doi:10.1038/nrd1012. ISSN 1474-1776. PMID 12563306. S2CID 21954007.
Baker, H. (18 August 1979). ""Medical Hubris"". Canadian Medical Association Journal (Letter to the editor). 121 (4): 405–406. PMC 1704398. PMID 20313336.
Horrobin, David F. (2001). "Something rotten at the core of science?". Trends Pharmacol Sci. 22 (2): 51–2. doi:10.1016/S0165-6147(00)01618-7. PMID 11166837. Archived from the original on 14 August 2007. Retrieved 16 September 2009.

nytimes.com

"F.D.A. in Battle on Health Food Frauds". The New York Times. 1 June 1989. Archived from the original on 6 July 2022. Retrieved 7 February 2017.
"Scotia's Unusual Approach May Yet Silence Critics : A Small Drug Firm Thinks Big" Erik Ipsen, The New York Times, 27 May 1995.

nzherald.co.nz

Reid, Graham (7 June 2001). "New book suggests schizophrenia shaped humankind". New Zealand Herald. Wilson & Horton. Retrieved 26 March 2024.

pcc.org.uk

"Mr Adam Kelliher complained to the Press Complaints Commission, on behalf of the family of the late Dr David Horrobin" Press Complaints Commission, Report 63.

pharmj.com

"Epogam and Efamast lose product licences". The Pharmaceutical Journal. 269 (7215): 352. September 2002. Archived from the original on 4 December 2008. Retrieved 15 September 2009.
"Scotia placed in administration after EMEA rejects Foscan". The Pharmaceutical Journal. 266 (7133): 143. 2001. Archived from the original on 24 May 2010. Retrieved 16 September 2009.
"Keeping an open mind" Archived 12 October 2008 at the Wayback Machine Murphy J., The Pharmaceutical Journal, 1 May 2004 Vol 272 No 7297 p543.

pressgazette.co.uk

"BMJ apologises for 'insensitive' obituary of doctor" Archived 16 June 2011 at the Wayback Machine Jon Slattery, Press Gazette, 25 July 2003.

prospectmagazine.co.uk

Warts ‘n’ all obituaries Prospect Magazine, Patrick West, 20 July 2003

quackwatch.org

"Primrose Oil and Eczema: How Research Was Promoted and Suppressed" Stephen Barrett, Quackwatch, 31 January 2004.

queensu.ca

post.queensu.ca

Horrobin, David F. (2001). "Something rotten at the core of science?". Trends Pharmacol Sci. 22 (2): 51–2. doi:10.1016/S0165-6147(00)01618-7. PMID 11166837. Archived from the original on 14 August 2007. Retrieved 16 September 2009.

royalsociety.org

"Prizes for Science Books – previous winners and shortlists". Retrieved 16 September 2009.

secinfo.com

Amarin Corporation 2nd quarter 2004 statement of results.

semanticscholar.org

api.semanticscholar.org

Horrobin, David F. (2003). "Modern biomedical research: an internally self-consistent universe with little contact with medical reality?". Nature Reviews Drug Discovery. 2 (2): 151–154. doi:10.1038/nrd1012. ISSN 1474-1776. PMID 12563306. S2CID 21954007.
Oransky, I. (2003). "Obituary – David F Horrobin" (PDF). The Lancet. 361: 1395. doi:10.1016/s0140-6736(03)13046-2. S2CID 54267071.

telegraph.co.uk

"David Horrobin". The Telegraph (Obituary). London. 2 May 2003. Archived from the original on 29 June 2011. Retrieved 16 September 2009.
"Should we give the biotechies money to burn?" Rosie Murray-West, The Telegraph, 11 September 2004.
"Fat is an insanity issue" The Telegraph, 7 April 2001.

the-scientist.com

"First Publication For Seattle Theorist" The Scientist, 13 November 1989.

theguardian.com

"How to avoid the bitter pill of regulation" Ben Goldacre, Bad Science Column, The Guardian, 23 September 2003.
"'A rotter, a snake oil salesman, a chancer' – how scientist's obituary sparked a storm. A vitriolic attack in the British Medical Journal has devastated eminent academic David Horrobin's family, reports Robin McKie" Robin McKie, The Observer, in The Guardian, 25 May 2003.
Clark, Andrew (26 January 2001). "Scotia collapses into bickering. The arguments get personal as trading in biotech firm's shares is halted". The Guardian. London. Retrieved 14 September 2009.
"The human stain. The Madness of Adam and Eve by David Horrobin asks the question: did schizophrenia make us sapient?" John McCrone, The Guardian, 28 April 2001.
"How a novelist's twist sparked academic feud. When the feted author of Birdsong slipped a recent psychiatric idea into his work, one don saw red" Vanessa Thorpe, The Guardian, 21 August 2005.

timeshighereducation.co.uk

"A polluted puddle of poetry and psychosis" David Pilgrim, Times Higher Education, 5 October 2001.

timesonline.co.uk

business.timesonline.co.uk

Court, Mark (2 April 2003). "Pioneer of UK biotechnology dies of cancer". The Times. Archived from the original on 12 June 2011. Quote: "Dr Horrobin was best known for creating Scotia Holdings, a once sprawling biotechnology company which has the unfortunate distinction of being the UK’s only quoted biotechnology company to have collapsed into administration."
"Fraud charge deals fresh blow to Scotia investors" Mark Court, The Times, 11 March 2003.

timesonline.co.uk

"Gulf War syndrome doctor faked £90m trial for diabetes drug" Ronan McGreevy, The Times, 28 March 2003.
"Obituary: David Horrobin". The Times. London. 9 April 2003. Retrieved 15 September 2009.

web.archive.org

Court, Mark (2 April 2003). "Pioneer of UK biotechnology dies of cancer". The Times. Archived from the original on 12 June 2011. Quote: "Dr Horrobin was best known for creating Scotia Holdings, a once sprawling biotechnology company which has the unfortunate distinction of being the UK’s only quoted biotechnology company to have collapsed into administration."
"F.D.A. in Battle on Health Food Frauds". The New York Times. 1 June 1989. Archived from the original on 6 July 2022. Retrieved 7 February 2017.
"Epogam and Efamast lose product licences". The Pharmaceutical Journal. 269 (7215): 352. September 2002. Archived from the original on 4 December 2008. Retrieved 15 September 2009.
"David Horrobin". The Telegraph (Obituary). London. 2 May 2003. Archived from the original on 29 June 2011. Retrieved 16 September 2009.
Richmond, C. (17 April 2003). "David Horrobin – Champion of evening primrose oil". The Independent. London. Archived from the original on 13 March 2010. Retrieved 15 September 2009.
"Scotia placed in administration after EMEA rejects Foscan". The Pharmaceutical Journal. 266 (7133): 143. 2001. Archived from the original on 24 May 2010. Retrieved 16 September 2009.
Horrobin, David F. (2001). "Something rotten at the core of science?". Trends Pharmacol Sci. 22 (2): 51–2. doi:10.1016/S0165-6147(00)01618-7. PMID 11166837. Archived from the original on 14 August 2007. Retrieved 16 September 2009.
"Keeping an open mind" Archived 12 October 2008 at the Wayback Machine Murphy J., The Pharmaceutical Journal, 1 May 2004 Vol 272 No 7297 p543.
"BMJ apologises for 'insensitive' obituary of doctor" Archived 16 June 2011 at the Wayback Machine Jon Slattery, Press Gazette, 25 July 2003.
Stephen S. Chang Award Archived 10 April 2008 at the Wayback Machine

worldcat.org

Horrobin, David F. (2003). "Modern biomedical research: an internally self-consistent universe with little contact with medical reality?". Nature Reviews Drug Discovery. 2 (2): 151–154. doi:10.1038/nrd1012. ISSN 1474-1776. PMID 12563306. S2CID 21954007.
Horrobin, David F. (1977). Medical Hubris: A Reply to Ivan Illich. Montreal, Canada: Eden Press. ISBN 978-0-88831-001-9. OCLC 299992755.